Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson 1Q

Worldwide pharmaceutical sales were $5.8 billion in the quarter (-10%) with an operational decline of 5% and a negative impact from currency of 5%. Domestic sales were down 10%.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 1Q

1Q Revenues: $15.0 billion (-7%)

1Q Earnings: $3.5 billion (-3%)

Comments: Worldwide pharmaceutical sales were $5.8 billion in the quarter (-10%) with an operational decline of 5% and a negative impact from currency of 5%. Domestic sales were down 10%. International sales were down 11%, which reflected an operational increase of 3% and a negative currency impact of 14%. Concerta sales were up 19% to $344 million; Remicade sales were $1.0 billion (+3%); Invega sales were $91 million (+38%); Risperdal Consta sales were $325 million (+5%); and Velcade sales were $192 million (+4%). Risperdal sales were down 66% to $275 million due to generic competition and sales of Procrit were down 13% to $550 million due to a decline in the market. Worldwide consumer sales were $3.7 billion in the quarter (-9%). Worldwide Medical Devices and Diagnostics sales were $5.5 billion (-3%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters